Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anifrolumab - AstraZeneca

X
Drug Profile

Anifrolumab - AstraZeneca

Alternative Names: Anifrolumab-fnia - AstraZeneca; Anti-IFNaR MAb - AstraZeneca; MDX-1333; MEDI-546; SAPHNELO; Saphnelo

Latest Information Update: 17 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer AstraZeneca; Medarex; MedImmune
  • Class Antirheumatics; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action Interferon alpha beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Systemic lupus erythematosus
  • Phase III Lupus nephritis; Scleroderma
  • Phase II Sjogren's syndrome
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 12 Jun 2024 AstraZeneca plans a phase III trial for Polymyositis and Dermatomyositis in USA, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Poland, Spain, Sweden, Taiwan, UK, Vietnam (SC) in June 2024 (NCT06455449)
  • 14 Mar 2024 Phase-III clinical trials in Systemic lupus erythematosus (Adjunctive treatment, In children, In adolescents) in USA, Turkey (IV) (NCT05835310)
  • 10 Nov 2023 Efficacy data from a phase III TULIP SLE LTE trial in Systemic lupus erythematosus presented at ACR Convergence 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top